Share this to:

Support & Insight for the Autumn of Life

Lecanemab Enters Advanced Alzheimer’s Gene Trials


Phase II/III trials are begining in the Tau NextGen study. The study will assess the effect of Lecanemab, an experimental anti-amyloid therapy, in pre-symptomatic or symptomatic participants who have an Alzheimer’s-causing gene mutation. Learn more.

The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, has enrolled the first subject in the Phase II/III study (Tau NexGen study). The DIAN is an international research effort focused on dominantly inherited Alzheimer’s disease.

The study will assess the effect of Eisai’s investigational anti-microtubule binding region (MTBR) tau antibody E2814, in dominantly inherited Alzheimer’s disease (DIAD).

What this study examines

People who have genetic mutations of DIAD, a rare form of Alzheimer’s disease (AD) that causes memory loss and dementia, are likely to develop symptoms at around the same age their affected parents did, often in their 50s, 40s or even 30s.

The major AD pathologies are amyloid plaque that consists of amyloid beta (Aβ) aggregates; neurofibrillary tangles; and intraneuronal aggregates of tau, all of which are believed to spread throughout the brain.

The purpose of the Tau NexGen (New Window) study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational therapies in pre-symptomatic or symptomatic participants who have an AD-causing gene mutation.

Lecanemab targets amyloid

The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) is an international public-private partnership dedicated to designing and managing interventional therapeutic trials for individuals with and at risk of DIAD. The DIAN-TU is dedicated to finding solutions to treat or prevent this disease and, potentially, all forms of Alzheimer’s.

In March 2021, the DIAN-TU selected E2814, which was created from a research collaboration between Eisai and University College London, as the first investigational medicine among anti-tau drugs for the Tau NexGen study.

With increasing evidence from clinical studies showing that targeting amyloid can reduce biomarkers of Alzheimer’s disease, the Tau NexGen(New Window) clinical trial leaders then selected Eisai’s investigational anti-Aβ protofibril antibody lecanemab (BAN2401) as the background anti-amyloid therapy, and the study design was amended in November 2021.


Notify of

Inline Feedbacks
View all comments
B. Berger

B. Berger

Visit Our Pages On:


This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chaffe, the important articles & videos from each week’s river of news. With a new post on Alzheimer’s or dementia appearing on the internet every 7 minutes, the site’s focus on the best information has been a help to many over the past 15 years. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor


hearing aid, hearing, ears
Hearings Aids Offer Dementia Prevention
Studies have found an association between hearing loss and the development of dementia in older adults. Research also...
man and woman sitting on bench facing sea
Is Sitting Bad for the Brain? Maybe Not.
Is keeping seated and sedentary, while intellectually stimulated, part of the best way to care for your brain?
dna, biology, medicine
The Genetic Factor That Fends Off Alzheimer's
A massive study of medical and genetic data shows that people with a particular version of a gene involved in immune...
Would love your thoughts, please comment.x
News, Treatments, Care Tips

Subscribe To The Weekly Newsletter

videos & articles on Research & Prevention
News to Get at the Truth

Subscribe To Our Weekly Newsletter